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Sox9 and programming of liver  
and pancreatic progenitors
Yoshiya Kawaguchi
Department of Clinical Application, Center for iPS cell Research and Application (CiRA), Kyoto University, Kyoto, Japan.
Recent advances in developmental biology have greatly expanded our understanding of progenitor cell program-
ming and the fundamental roles that Sox9 plays in liver and pancreas organogenesis. In the last 2 years, several stud-
ies have dissected the behavior of the Sox9+ duct cells in adult organs, but conflicting results have left unanswered 
the long-standing question of whether physiologically functioning progenitors exist in adult liver and pancreas. On 
the other hand, increasing evidence suggests that duct cells function as progenitors in the tissue restoration process 
after injury, during which embryonic programs are sometimes reactivated. This article discusses the role of Sox9 in 
programming liver and pancreatic progenitors as well as controversies in the field.
Introduction
Mechanisms of organogenesis and adult organ maintenance have 
attracted the interest of not only basic scientists but also clinicians, 
because such research deepens our understanding of disease patho-
genesis and provides a basis for exploring new therapies. Indeed, the 
proposed concept of cancer stem/initiating cells, which is essentially 
analogous to stem cells in organogenesis, has been experimentally 
validated for some tumors, and researchers hope to develop thera-
peutics that specifically target these cells (1–5). Notably, many sim-
ilarities exist between the cellular processes of tissue regeneration 
and tumorigenesis, such as aggressive cell proliferation, migration, 
and epithelial-mesenchymal transition, in which embryonic gene 
sets are sometimes reactivated (6–10). This notion illustrates the 
importance of developmental biology research and, in particular, 
the characterization of organ-specific progenitors.
Sex-determining region Y–box (SRY-box) containing gene 9 
(Sox9), a member of the SRY-related, high-mobility group box 
(Sox) transcription factors, is mutated in campomelic dyspla-
sia, a disorder characterized by skeletal malformations, XY sex 
reversal, and neonatal lethality (11). Sox9 is expressed during 
embryogenesis in several tissues and organs including chon-
drocytes, testes, heart, lung, pancreas, bile duct, hair follicles, 
retina, and the central nervous system (12–21). Sox9 functions, 
in general, to maintain cells in an undifferentiated state dur-
ing embryonic development. In the last few years, the role of 
Sox9 in the organogenesis and maintenance of adult liver and 
pancreas has been vigorously investigated. However, conflict-
ing results exist on the behavior of adult Sox9+ cells (22–24). 
In this article, rather than simply rehashing the latest studies, 
I attempt to dissect the role of Sox9 in the programming of the 
liver and pancreas progenitors and to provide clinical aspects of 
diseases related to Sox9.
Cre-based genetic lineage tracing uncovers cell behavior 
in vivo
To understand the behavior of specific cells in vivo, either dur-
ing organogenesis or in the adult organ, reliable analytical meth-
ods must be applied. An important advance in lineage-tracing 
experiments was the application of the Cre/loxP system (ref. 
25 and Figure 1). In this method, mice carry 2 transgenic gene 
cassettes: (a) a Cre recombinase gene expression cassette that 
is driven from a cell type–specific promoter (by conventional 
transgenesis, bacterial artificial chromosome [BAC] transgene-
sis, or knock-in to the endogenous locus of a cell type–specific 
marker gene), and (b) the floxed reporter allele whose expression 
is activated by Cre-mediated recombination (such as ROSA26r, 
in which a loxP–STOP–loxP–β-galactosidase gene cassette is 
knocked in to the ubiquitously expressed ROSA26 locus) (26). 
To mark cells in a temporal manner, Cre can be fused with the 
ligand-binding domain of the estrogen receptor (CreER or its 
variants), rendering its activity tamoxifen inducible. The addi-
tion of tamoxifen drives the CreER fusion protein into the 
nucleus. Recombination disrupts the STOP cassette within the 
reporter allele and thereby permanently marks cells by reporter 
expression. Because recombination occurs within the genomic 
DNA, this mark is inherited by all descendants of the labeled cell 
regardless of its subsequent cell fate(s).
Sox9 in embryonic pancreas and liver
Developmentally, the pancreas and liver originate from the 
foregut endoderm. In the pancreas, Sox9 is expressed in all 
epithelial cells at early developmental stages; its expression is 
confined to the duct cells as development proceeds. Differenti-
ated acinar and endocrine cells do not express Sox9 (22, 27). The 
fate of embryonic Sox9+ cells was independently analyzed using 
different Sox9-CreER mouse lines. Lineage-tracing experiments 
using either BAC Sox9-CreER transgenic (23) or Sox9-IRES-CreER 
knock-in mice (22) showed that all types of pancreatic epithelial 
cells including endocrine, acinar, and duct cells were labeled, 
suggesting a common origin from Sox9-expressing progeni-
tors. This notion is supported by another pseudo–short-term 
cell-tracking experiment that took advantage of the half-life of 
GFP in Sox9-EGFP transgenic mice (27).
What is the role of Sox9 in pancreatogenesis? Pathological anal-
yses on autopsy samples from 3 humans with campomelic dyspla-
sia showed impaired pancreas formation described as “less densely 
packed epithelial cells within the mesenchymal stroma and less 
clearly formed islets” (28). Campomelic dysplasia is an autoso-
mal-dominant disease caused by SOX9 haploinsufficiency, sug-
gesting a dosage requirement for Sox9 in pancreatic development; 
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this notion is consistent with observations that Sox9 heterozygous 
mutant mice die perinatally (11, 16, 29, 30). When Sox9 gene dosage 
was experimentally reduced to 50% in murine pancreatic progen-
itors, the number of neurogenin 3–expressing (Ngn3-expressing) 
endocrine progenitors was reduced, resulting in less endocrine cell 
formation, whereas exocrine mass was not impaired (27). These 
findings indicate that the pancreatic endocrine lineage is more sen-
sitive than the exocrine lineage to Sox9 dosage, in accordance with 
the endocrine-dominant impairment in cases of humans with cam-
pomelic dysplasia (28). On the other hand, pancreas-specific Sox9 
depletion in mice resulted in severe pancreas hypoplasia, suggest-
ing that Sox9 functions in the expansion of the pool of multipotent 
progenitor cells by accelerating their proliferation and survival and 
by keeping them in an undifferentiated state in early pancreatic 
development (16).
How is Sox9 regulated during pancreatogenesis? Recent reports 
showed that the involvement of FGF and Notch signaling path-
ways are conserved between mouse and zebrafish (refs. 31–35 and 
Figure 2). During early pancreatic development, FGF receptor 2b 
(Fgfr2b) expressed in the Sox9+ epithelium transduces a mesenchy-
mally derived Fgf10 signal. Expression of Fgfr2b is regulated by 
Sox9. Moreover, Fgf10 is required to maintain the expression of 
Fgfr2b and Sox9 in pancreatic progenitors. This Fgf10/Fgfr2b/
Sox9 feed-forward loop in the early pancreatic niche is pivotal 
not only for the expansion of the pancreatic precursors, but also 
for the maintenance of organ identity (33). Inactivation of either 
Fgf10 or Sox9 in pancreatic progenitors results in the emergence 
of α-fetoprotein–positive cells in the pancreatic rudiment, suggest-
ing a conversion in organ identity from pancreas to liver (33).
In pancreatic endocrine differentiation, there exists a complicated 
but well-organized molecular circuitry involving Sox9, Notch, Hes1, 
and Ngn3 (ref. 32 and Figure 2). Notch signaling activates Sox9 
expression within the primitive epithelium. Sox9, in turn, is required 
for the induction of Ngn3, an indispensable gene for endocrine dif-
ferentiation. At the same time, Ngn3 is negatively regulated by the 
Notch effector Hes1 (32, 36, 37). Thus, Ngn3 is regulated by the bal-
ance of Sox9 and Hes1. At high Notch activity, Hes1 activity predom-
inates over Sox9, resulting in Ngn3 downregulation. To complete 
endocrine differentiation, Sox9 expression is subsequently silenced. 
In this process, cell-autonomous repression of Sox9 by Ngn3 and 
evasion from Notch activity seems to be crucial. At the same time, 
Sox9 regulates Hes1, and the number of Hes1+ cells is reduced by 
Sox9 depletion (16). These results suggest the existence of a mutual 
regulatory system between Sox9 and Notch/Hes1/Ngn3 signals, in 
which dosage or strength of the signals controls the proliferation 
and differentiation of the pancreatic endocrine precursors (32). In 
contrast, regulation of Sox9 in exocrine pancreatic development has 
been poorly investigated. One hypothesis is that a similar mechanism 
operates in exocrine precursors, with pancreas-specific transcription 
factor 1a (Ptf1a) substituting for Ngn3. Ptf1a initially functions as 
the pancreatic-determinant gene during the fate separation of the 
primitive gut epithelia into the duodenum, pancreas, and bile duct 
lineages (38, 39). In addition, Ptf1a is indispensable for acinar cell dif-
ferentiation (38, 40). Dosage control of Ptf1a is important for both 
functions; Ptf1a reduction causes the fate conversion of pancreatic 
precursors into the duodenal and bile duct cells and decelerates pro-
liferation and differentiation in the exocrine lineage (39). In addition, 
autoregulation of Ptf1a to maintain Ptf1a dosage plays a part in the 
Figure 1
Tamoxifen-inducible Cre-mediated lineage tracing. Cre recombinase is fused with the ligand-binding domain of the estrogen receptor. Tamoxifen 
administration enables the CreER fusion protein to enter the nucleus then excise the STOP cassette of ROSA26r, resulting in permanent labeling 
of the progeny. Such strategies have been instrumental to understanding the role of Sox9 in pancreatic and liver progenitor cells.
Figure 2
Maintenance of pancreatic fate and gene regulation in the programming 
of pancreatic endocrine progenitors. A Fgf10/Fgfr2b/Sox9 feed-forward 
loop functions in the maintenance of pancreatic fate and expansion of 
early pancreatic precursors. Sox9 promotes the expression of Fgfr2b, 
which transduces signaling from Fgf10. Moreover, Fgf10 signaling pro-
motes the expression of Fgfr2b and Sox9 in pancreatic progenitors. 
In the endocrine differentiation, a parallel regulatory circuitry exists, 
involving Notch, Hes1, Sox9, and Ngn3 (31–33).
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final maturation of the acinar cells (41, 42). Like Ngn3, Ptf1a is also 
negatively regulated by Hes1 (43). These lines of evidence support the 
hypothesis that Sox9 and a Notch/Hes1/Ptf1a axis control exocrine 
development, but future experiments are needed for confirmation.
In liver development, hepatoblasts and hepatocytes do not express 
Sox9, but Sox9 is detected in cholangiocytes (17, 22). Notably, 
lineage tracing using Sox9-IRES-Cre knock-in mice provided evi-
dence that embryonic Sox9+ cholangiocytes can differentiate into 
hepatocytes, although only a subset of hepatocytes was labeled, pre-
dominantly in the hilar region at P1 (22). Similar results were also 
obtained using BAC Sox9-CreER transgenic mice (44). Construction 
of the intrahepatic biliary tree originates in the hilum and expands 
toward the periphery. Morphologically, tubular formation of the 
ducts begins with the formation of an asymmetrical primitive duc-
tal structure in which Sox9+ cholangiocytes are located on the por-
tal side and Sox9– hepatoblasts are on the parenchymal side (17). 
After a maturation step involving TGF-β signaling, the biliary tube 
is entirely composed of Sox9+ cholangiocytes. Embryonic liver-spe-
cific inactivation of Sox9 in mice resulted in a delay in duct matu-
ration. Thus, Sox9 determines the timing of bile duct morphogen-
esis (17). In addition, Notch definitively functions in the formation 
of bile duct structure and regulates Sox9 as seen in the etiology of 
Alagille syndrome, an autosomal-dominant genetic disorder caused 
by mutations in the Notch pathway (17, 45–48). Notch regulation 
of Sox9 in the liver may be functionally analogous to its role in the 
pancreas, but Notch targets in the liver that correspond to Ngn3 
and Ptf1a in pancreas formation have yet to be identified.
Do physiologically functioning stem/progenitor cells 
exist in adult liver and pancreas?
To maintain the functional homeostasis of an adult organ, which is 
composed of several cell types, either in the physiological state or dur-
ing the regenerative process after injury, an orchestrated mechanism 
must ensure the correct supply or elimination of each cell type and 
the maintenance of tissue architecture. In the skin and gut, organ-spe-
cific stem cells located in the bulge of the outer root sheath of hair 
follicles and those in the intestinal crypt, respectively, continuously 
supply new cells, while the homeostatic elimination of old cells occurs 
in the skin surface and at the top of the intestinal villi, respectively (49, 
50). Along with cell replacement in a streaming manner, tissue archi-
tecture is maintained. How such homeostasis is achieved in the case 
of the adult liver and pancreas remains an important question for the 
long-term efficacy of cell transplantation therapies such as proposed 
hepatocyte transplantation in pediatric patients (51).
In the 1980s, Zajicek et al. proposed a “streaming hypothesis” 
from their observations that adult hepatic cells marked by triti-
Figure 3
The continuous Sox9-expressing domain in adults. Sox9 expression is detected throughout the pancreatic ducts, intra- and extrahepatic ducts, 
and in the intestinal crypt connected through the papilla of Vater, forming a contiguous Sox9+ zone.
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ated thymidine incorporation migrated from the periportal region 
to the central vein region under physiological condition in rats 
(52–58). However, in the 1990s a heated debate on the streaming 
hypothesis erupted based on Bralet’s experiments showing that 
rat hepatic cells marked by the retrovirus-mediated β-galacto-
sidase gene expression did not stream (59). More recently, another 
report provided support for the streaming liver hypothesis (60). 
Fellous et al. showed that patches of cytochrome c oxidase–defi-
cient hepatocytes that abut the portal tracts expanded toward the 
hepatic vein in human liver (60). Because cytochrome c oxidase is 
encoded by mitochondrial DNA, they used mitochondrial DNA as 
a marker of clonal expansion. They demonstrated that cytochrome 
c oxidase–deficient patches were clonal, suggesting an origin from 
long-lived cells such as stem cells located in the periportal region 
(60). Lineage-tracing experiments using Sox9-IRES-CreER knock-in 
mice and BAC Sox9-CreER transgenic mice demonstrated that adult 
Sox9+ bile duct cells at the periportal region physiologically supply 
new hepatocytes (22, 24). In Sox9-IRES-CreER knock-in mice, the 
newly formed hepatocytes appear to migrate very slowly from the 
periportal space to the central vein, as observed in the experiments 
with high-dose tamoxifen treatment (5 tamoxifen injections of 
4 mg/20 g body weight), supporting the original “streaming 
hypothesis” (22). However, hepatocyte differentiation from the 
Sox9+ cells was limited to the periportal region in BAC Sox9-CreER 
transgenic mice (24). One criticism that arose against the tamox-
ifen-inducible Cre-based experiments is that tamoxifen injection 
causes hepatocyte toxicity and may result in ectopic Sox9 expres-
sion in hepatocytes. Indeed, a single injection of 10 mg/kg body 
weight of tamoxifen causes ectopic Sox9 expression in hepatocytes 
within 18 hours (44); however, this cannot explain the results of 
the previously mentioned Sox9 lineage-tracing experiments, since 
ectopic Sox9 expression is not restricted to periportal hepatocytes.
More recently, 2 tamoxifen-independent tracing experiments were 
reported (61, 62). Malato et al. used AAV-mediated hepatocyte label-
ing that argued against physiologically functioning progenitors in 
ducts (61). In this report, virus-mediated induction of Cre recombi-
nase under the hepatocyte-specific transthyretin (Ttr) promoter in 
ROSA26-YFP reporter mice successfully labeled all the hepatocytes 
without any leaky labeling of Sox9+ duct cells. Following a 12-week 
chase, the liver did not contain yellow fluorescent protein–negative 
(YFP–) hepatocytes, indicating that hepatocyte mass is maintained 
solely through hepatocyte proliferation and that Sox9+ duct cells do 
not participate in maintaining adult organ homeostasis by differen-
tiating into hepatocytes. On the contrary, Iverson et al. performed 
unique experiments that provided evidence of new hepatocyte sup-
ply in adults (62). Using Albumin-Cre;ROSAmT-mG mice that convert 
from tdTomato expression to EGFP expression via Cre-mediated 
recombination, they revealed that a steady-state level of 0.076% of 
all hepatocytes had differentiated within the previous 4 days from 
albumin-naive precursors (62).
There has been a long-standing debate about whether physiologi-
cally acting stem/progenitor cells exist in the ductal structure of the 
adult pancreas. Studies have shown that embryonic Sox9+ duct cells 
can differentiate into pancreatic acinar and endocrine cells (22, 23). 
Because Sox9 expression persists throughout the epithelium of the 
adult pancreatic ductal tree, including centroacinar cells (Figure 3) 
(22), much interest has focused on the differential ability of adult 
Sox9+ cells. Lineage-tracing experiments using BAC Sox9-CreER 
transgenic mice demonstrated that Sox9+ duct cells lose their differ-
entiation ability within a few days after birth. Thus, adult Sox9+ duct 
cells do not function as stem/progenitor cells in BAC Sox9-CreER 
transgenic mice (23). This finding is in accordance with another 
lineage-tracing experiment targeted to adult pancreatic cells; adult 
Hnf1β+ ductal cells do not differentiate into acinar/endocrine cells 
(63). Moreover, pulse and chase experiments using RIP-CreER (64) 
or elastase-CreER (65) supported the notion that adult pancreatic 
β cells and acinar cells are maintained by the self-duplication of 
preexisting cells rather than by differentiation from progenitors 
(66). Taken together, most of these results refute the existence of 
stem/precursor cells in the adult pancreatic duct. On the contrary, 
lineage tracing using Sox9-IRES-CreER knock-in mice showed essen-
tially identical results to BAC Sox9-CreER transgenic mice during 
embryonic and neonatal stages, but differences between these two 
Sox9-CreER lines were seen in adult pancreas. In contrast to BAC 
Sox9-CreER–labeled cells, adult pancreatic Sox9+ ducts continuously 
supply new acinar cells in Sox9-IRES-CreER knock-in mice (22).
In examining these conflicting results from different Sox9-CreER 
lines, 2 potential pitfalls of the lineage-tracing experiments should be 
considered. First, differences in the initially marked cell population 
would naturally cause different results. For example, there exist Hes1+ 
and Hes1– cells in pancreatic ducts. Thus, lineage-tracing results of 
adult Hes1+ cells do not directly negate the existence of precursors 
in ducts. A detailed comparison of CreER expression in the different 
Sox9-CreER lines would be required to assess such variation. A more 
probable explanation is that the cell behavior is unexpectedly altered 
by the insertion of the transgenic cassette into the Sox9 locus. In Sox-
9-IRES-CreER knock-in mice, the dosage of Sox9 expression might be 
altered even though the introduced CreER cassette contains an IRES 
sequence. Preliminary data from our lab showed that Sox9 expression 
levels in the pancreas and liver were not altered in newborn pups but 
were reduced in adult Sox9-IRES-CreER knock-in mice compared with 
wild-type mice (Shinichi Hosokawa and Masashi Horiguchi, personal 
communication). This observation suggests that the 3′ non-coding 
region of the Sox9 locus that is altered by the IRES-CreER cassette 
insertion (22) is pivotal for Sox9 regulation in adults but not in embry-
onic and newborn stages. Though not yet experimentally confirmed, 
we suspect that the dosage of Sox9 is not altered in BAC Sox9-CreER 
transgenic mice. Thus, not only during development, but also in the 
adult organs, Sox9 expression levels appear to be crucial for control-
ling the cell status of the duct cells. Additional experiments, such as 
reducing the Sox9 dosage in adult pancreatic duct cells combined with 
lineage tracing using BAC Sox9-CreER, are of interest.
Kopinke et al. reported that adult Hes1+ cells occasionally 
observed in the pancreatic ducts and centroacinar cells do not dif-
ferentiate into acinar cells in a physiological state, but that inactiva-
tion of Rbpj (also known as recombining binding protein suppres-
sor of hairless) in Hes1+ cells causes rapid differentiation into acinar 
cells (67, 68). Thus, Notch functions to preserve the pancreatic duct 
cell identity in the ductal tree. Considering that Ptf1a is negatively 
regulated by Hes1 in embryonic stages and that reduced Ptf1a 
dosage impairs exocrine development (39, 43), it is possible that 
Notch/Rbpj/Hes1-mediated Ptf1a repression prevents acinar cell 
differentiation in adult duct/centroacinar cells. If this is the case, a 
similar mechanism may operate in controlling the differentiation 
capacity of adult Sox9+ centroacinar cells as in embryonic stages. As 
mentioned, there exists mutual regulation among Sox9, Notch, and 
Hes1 during embryonic pancreatogenesis (Figure 2). In Sox9-CreER 
knock-in mice, reduced Sox9 expression in adult centroacinar cells 
may result in reduced Notch-Hes1 activity, resulting in continuous 
acinar cell differentiation through Ptf1a acceleration.
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Along these lines, cell turnover in the adult organ would be rapid 
in a Sox9-IRES-CreER knock-in mouse, since its organ size is not 
apparently bigger than that of the wild-type animal. Indeed, the per-
centage of proliferating Sox9+ cells is reported to decrease in adult 
liver in BAC Sox9-CreER transgenic mice (44), but our preliminary 
results showed more pHH3-positive cells in the liver and pancreas in 
adult Sox9-IRES-CreER knock-in mice compared with the adult wild-
type mice (Shinichi Hosokawa and Masashi Horiguchi, personal 
communication). Since the roles of Sox9 in adult pancreas and liver 
are not well known, a dosage control of Sox9 in adult organs may 
be an open area for further investigation, not only in physiological 
organ homeostasis but also in regeneration and carcinogenesis.
Duct cells in the regeneration of liver and pancreas
As mentioned above, it is still unclear whether duct cells function as 
physiological progenitors in adult liver and pancreas. However, accu-
mulating evidence supports the existence of precursors in the ducts 
that can respond to tissue injuries and participate in the restoration 
process, although the extent of their contribution differs depending 
on the type and degree of injury. For example, pancreatic Sox9+ duct 
cells do not differentiate into endocrine cells after pancreatic duct 
ligation, partial pancreatectomy, cerulein-induced pancreatitis, or 
in a streptozotocin-induced diabetes model (22, 69). After extensive 
β cell ablation using diphtheria toxin receptor-expressing transgenic 
mice, transdifferentiation of α cells into β cells was observed (70), but 
not differentiation of Sox9+ duct cells into β cells (69). In contrast, 
extensive diphtheria toxin–induced depletion of both acinar and 
endocrine cells combined with Pdx1-Cre as a lineage-tracing system 
showed that the remaining cells in the ductal component contrib-
uted to the regeneration of both endocrine and acinar cells (10).
In Sox9-IRES-CreER knock-in mice, proliferation of the Sox9+ bile 
duct cells and subsequent hepatocyte differentiation is accelerated 
by injuries including acute carbon tetrachloride (CCl4), bile duct 
ligation, and methionine- and choline-deficient diet supplemented 
with 0.15% ethionine. Other injury models such as 70% partial hepa-
tectomy, 3,5-diethoxycarbonyl-1,4-dihydrocollidine–supplemented 
(DDC-supplemented) diet, and acetaminophen treatment result 
in moderate or low contribution of Sox9+ duct cells to the regen-
erating tissue (22). In the DDC model, accelerated hepatocyte dif-
ferentiation of Sox9+ cells was also observed in the BAC Sox9-CreER 
transgenic mice (24). Of note, Malato et al. detected lineage-negative 
hepatocytes, although small in number, emerging after some hepatic 
injuries in AAV-Ttr-Cre mice (61). They showed that non-hepatocyte 
cells contributed to organ repair after chronic CCl4 exposure, 2/3 
partial hepatectomy, bile duct ligation of the left lobe, and DDC diet, 
and they speculated that these newly generated cells are of duct cell 
origin (61). Overall, these findings are in accordance with the results 
obtained by Sox9-IRES-CreER mice with the exception in CCl4 mod-
els; Malato et al. found contribution of non-hepatocyte cells after 
chronic CCl4 exposure but not by the acute CCl4 model (61), whereas 
Sox9+ bile duct cells function as the source of hepatocyte regenera-
tion by the acute CCl4 model in Sox9-IRES-CreER knock-in mice (22).
Future perspectives
Many researchers in the field have suggested that duct cells are the 
best candidates for the origin of human pancreas ductal adeno-
carcinoma (PDAC) and cholangiocarcinoma (CCC). However, in 
mouse models, accumulating evidence suggests that metaplasia of 
differentiated acinar cells and hepatocytes to a ductal phenotype 
is the key event in the initiation of PDAC and CCC, respectively 
(71–78). In this process, Notch appears to play a fundamental role; 
inactivation or activation of Notch signaling in acinar cells and 
hepatocytes does not cause any lesions, but the combination of 
Notch activation and carcinogenic signals (oncogenic Kras induc-
tion in acinar cells and thioacetamide administration or AKT 
overexpression in hepatocytes) results in conversion to a duct cell 
type (76–78). Interestingly, Sox9 is overexpressed in human hepa-
tocellular carcinoma, and its expression is associated with tumor 
progression and poor prognosis (79). More recently, ectopic expres-
sion of Sox9 and Hnf6, another pancreatic duct marker, has been 
reported in human metaplastic acinar cells associated with pancre-
atitis and pancreatic adenocarcinoma (80). Gain- and loss-of-func-
tion experiments using culture and mice suggest that Hnf6, and to 
a lesser extent Sox9, are required for the acinar-to-ductal metapla-
sia (80). The significance of Sox9 in other tumors and that in the 
experimental models is an area that warrants further investigation.
In summary, Sox9 plays a pivotal role in the programming of 
embryonic liver and pancreas progenitors. It is still unclear whether 
Sox9+ duct cells function as physiological progenitors in adult organ 
homeostasis, but these cells appear to be activated during the tissue 
regeneration process. Uncovering more mechanistic detail on the 
maintenance of the precursor status of embryonic Sox9+ cells and/or 
manipulation of Sox9 expression in adult cells may provide a basis for 
exploring new therapies for human diseases of the liver and pancreas.
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